Tango Therapeutics, Inc. (TNGX) Financial Statements
Tango Therapeutics, Inc. (TNGX) reported trailing twelve-month revenue of $53.8M (up 121.5% year on year) and net income of -$123.7M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$144.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TNGXTango Therapeutics, Inc.Follow TNGX — free
—
Price chart with a free account
- Market cap
- 3.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 0.04 | 0.02 | 0.04 | 0.04 | 0.06 | 0.05 | |
| Research & development | 0.08 | 0.11 | 0.12 | 0.14 | 0.13 | 0.13 | |
| Operating income | -0.06 | -0.11 | -0.11 | -0.15 | -0.11 | -0.14 | |
| Pre-tax income | -0.06 | -0.11 | -0.10 | -0.13 | -0.10 | -0.12 | |
| Income tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | |
| Net income | -0.06 | -0.11 | -0.10 | -0.13 | -0.10 | -0.12 | |
| Diluted EPS ($) | -0.94 | -1.23 | -1.08 | -1.19 | -0.87 | -0.83 | |
| Diluted shares (bn) | — | 0.088 | 0.095 | 0.109 | 0.116 | — |
USD billions · SEC XBRL
Tango Therapeutics, Inc. — questions
- What is Tango Therapeutics, Inc.'s revenue?
- $53.8M over the twelve months to 2026-06-30, up 121.5% year on year, from its 10-Q and 10-K filings.
- What is Tango Therapeutics, Inc.'s net income?
- -$123.7M over the twelve months to 2026-06-30.
- What is Tango Therapeutics, Inc.'s free cash flow?
- -$144.2M over the twelve months to 2026-06-30.
- What are Tango Therapeutics, Inc.'s diluted earnings per share?
- $-0.83 over the twelve months to 2026-06-30.
Every figure on this page comes from Tango Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.